Summary
Eli Lilly and Company (LLY) filed an 8-K on March 17, 2002, reporting on an event that occurred on March 12, 2002. The primary focus of this filing is the execution of an Underwriting Agreement concerning the issuance and sale of $500,000,000 in aggregate principal amount of 6.00% Notes due 2012. This transaction indicates the company's intention to raise significant capital through debt issuance, which could be for various corporate purposes such as funding operations, research and development, or potential acquisitions. Investors should note that the filing provides the form of the underwriting agreement and the note itself. While this 8-K does not contain detailed financial results or operational updates, it signals a material financial event for Eli Lilly. The issuance of debt implies a commitment to future interest payments and principal repayment, which will impact the company's leverage and financial obligations. Interested parties should review the full underwriting agreement and note terms for a complete understanding of the associated risks and benefits.
Key Highlights
- 1Eli Lilly and Company entered into an Underwriting Agreement on March 13, 2002.
- 2The agreement pertains to the issuance and sale of $500,000,000 in aggregate principal amount of 6.00% Notes Due 2012.
- 3The notes have a maturity date in 2012.
- 4The filing includes the form of the Underwriting Agreement and the form of the 6.00% Note Due 2012 as exhibits.
- 5This transaction represents a significant debt financing event for the company.
- 6The underwriting syndicate includes prominent financial institutions such as Goldman, Sachs & Co., J.P. Morgan Securities Inc., and Merrill Lynch Pierce, Fenner & Smith.